Our study further identified a higher interaction frequency of CD9 promoter-distal looping in resistant breast cancer cells and illustrated that such higher expression is evidently associated with lower survival probability in endocrine-resistant breast cancer patients (Fig. 5e, f). The gene discussed is CD9; the disease is breast cancer.